FLI1 gene influences lesion size and skin test may predict therapeutic response in cutaneous leishmaniasis.

Anadilton Santos Da Hora,Tainã Souza Do Lago,Paulo Roberto Machado,Léa Cristina Castellucci,Lucas Frederico De Almeida

doi:10.1590/0074-02760190361

Abstract

Genes associated with wound healing have been shown to be risk factors for cutaneous leishmaniasis (CL) which is caused by Leishmania braziliensis. In this study, we examined whether the genes previously associated with CL influenced the clinical outcome. Patients were genotyped and retrospectively classified as responders, who were cured with a single course of pentavalent antimony (Sbv), or as refractories, who did not respond to Sbv. Patients characterised as responders showed a stronger response to the leishmanin skin test (LST) when compared to the refractory subjects (p = 0.0003). Furthermore, we observed an association between the FLI1 CC genotype and an increased size of ulcers (p = 0.0170). We suggest that the leishmanin skin test may be a predictive tool for therapeutic outcome and reinforce FLI1 as a potential influencer of susceptibility and lesion size in CL.

Highlights

0,6070 0,4659 0,2142 0,0003 0,3080 (A) Induration area in the skin test of patients classified as refractories or responders according to the treatment with a pentavalent antimony. (B) Lesion size of patients with leishmaniasis according to the genotypes of the friend leukemia integration 1 (FLI1) gene
We observed a strong association between the CC genotype of the FLI1 gene and the patient’s lesion size, with larger lesions observed in the carriers of this genotype (p = 0.017), as shown in Figure (B)
The leishmanin skin test (LST) is one of the most common tests to diagnose cutaneous leishmaniasis (CL) as well as to confirm active or retrospective leishmaniasis in epidemiological surveys.[8]. Consistent with our results, a study in Brazil assessed the association between LST and therapeutic response and showed that the patients who did not respond to the treatment had less intense LST reactions than those who achieved clinical cure

Summary

SHORT COMMUNICATION

Anadilton Santos da Hora, Lucas Frederico de Almeida, Tainã Souza do Lago, Paulo Roberto Machado, Léa Cristina Castellucci1,2,3/+. We examined whether the genes previously associated with CL influenced the clinical outcome. Patients were genotyped and retrospectively classified as responders, who were cured with a single course of pentavalent antimony (Sbv), or as refractories, who did not respond to Sbv. Patients characterised as responders showed a stronger response to the leishmanin skin test (LST) when compared to the refractory subjects (p = 0.0003). We observed an association between the FLI1 CC genotype and an increased size of ulcers (p = 0.0170). We suggest that the leishmanin skin test may be a predictive tool for therapeutic outcome and reinforce FLI1 as a potential influencer of susceptibility and lesion size in CL. 2|3 Anadilton Santos da Hora et al

Clinical and demographic aspects

Findings

CI p